Clinical Trial: Efficacy and Safety of DA-3002 in Children With Idiopathic Short Stature

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Open, Multi-Center, Controlled, Randomized Phase III Clinical Trial to Evaluate the Efficacy and Safety of DA-3002(Recombinant Humn Growth Hormone)Treatment in Children With Idiopathic Same as current

Current Secondary Outcome: Difference of Height Standard Deviation Score Between Treatment and Non-treatment Group After 26 Weeks [ Time Frame: 26 weeks ]

The Height Standard Deviation Score was calculated as height minus reference mean height divided by the standard deviation of the reference mean height, both given by a reference growth table for the corresponding chronological age at the height measurement. Greater Height Standard Deviation Score indicates greater height.


Original Secondary Outcome: Difference of Height Standard Deviation Score Between Treatment and Non-treatment Group After 26 Weeks [ Time Frame: 26 weeks ]

Information By: Dong-A ST Co., Ltd.

Dates:
Date Received: February 6, 2013
Date Started: February 2012
Date Completion:
Last Updated: May 11, 2015
Last Verified: May 2015